ArticleMolecular medicine (Cambridge, Mass.)2025
NAT10 induces N4-acetylcytidine modification of AdipoR1-mediated mitochondrial biogenesis against endothelial-to-mesenchymal transition in hypertension.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEndothelial-to-mesenchymal transition (EndMT) in endothelial dysfunction exacerbates hypertension. However, the regulatory mechanisms underlying EndMT in hypertension are yet to be elucidated.
methodsThe N-acetyltransferase 10 (NAT10) and N4-acetylcytidine (ac4C) levels were determined in hypertensive mice, spontaneously hypertensive rats (SHRs), and angiotensin II (Ang II)-treated human umbilical vein endothelial cells (HUVECs). Biological functional assays were performed with lentiviral vectors to induce the overexpression or knockdown of NAT10 in vivo and in vitro. The detailed mechanisms underlying the role of ac4C-mediated posttranscriptional regulation in hypertension were investigated by combining ac4C-RIP-seq with RNA-seq, RIP-qRCR, mRNA stability, and dual-luciferase assays. Mitochondrial biogenesis and function were assessed via reactive oxygen species (ROS) and mitochondrial ROS (mtROS) staining; estimation of ATP levels, the mitochondrial membrane potential (MMP), and the mtDNA content; and evaluation of mitochondrial respiratory chain complex activities.
resultsThe results revealed that NAT10 and ac4C levels are higher in the hypertensive mice descending thoracic aorta tissues, SHRs descending thoracic aorta samples, and Ang II-treated HUVECs compared to the control groups. NAT10 overexpression inhibits EndMT in hypertension, which is partly due to the inhibition of endothelial dysfunction, whereas NAT10 inhibition has the opposite effect. Mechanistically, NAT10 inhibited endothelial dysfunction in hypertension through increased AdipoR1 mRNA ac4C acetylation. Moreover, NAT10 induced AdipoR1 expression, leading to increased mitochondrial biogenesis and function in Ang II-treated ECs via p38 MAPK/PGC-1α signaling.
conclusionsThe current data highlighted the molecular mechanisms of NAT10-induced ac4C acetylation and implied that the NAT10-AdipoR1 axis might be the therapeutic target to inhibit endothelial dysfunction and EndMT in hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.